FDA’s device center has finalized a new process for quickly disseminating updated guidelines for data expected in new product submissions.
FDA Issues Policy For Making Immediate Changes To Device Submission Guidelines
CDRH has posted a final standard operating procedure to describe how it will rapidly inform stakeholders of changes to expectations for new device submissions in the form of “Level 1, Immediately-in-Effect” guidance documents.